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Abstract 
Porcine circovirus associated disease (PCVAD) encompasses a group of syndromes linked to infection 
with porcine circovirus type 2 (PCV2). Based on the hypothesis that the immune responses to vaccination 
versus infection are quantitatively and qualitatively different, the objective of this study was to evaluate 
immunity, virus replication and disease protection in pigs vaccinated with PCV2 capsid protein (CP) and 
during infection. The disease model included dual infection with PCV2 and porcine reproductive and 
respiratory syndrome virus (PRRSV), a virus known to enhance disease progression and severity. The 
principal effect of PRRSV infection was to increase peak PCV2 viremia by almost 40-fold; however, PCV2 
failed to show a reciprocal effect on PRRSV. In vaccinated pigs, there was no evidence of disease or PCV2 
replication following dual virus challenge. Immunity following vaccination favored PCV2 neutralizing 
activity; whereas, PCV2 infection and disease produced high levels of non-neutralizing antibody, primarily 
directed against a polypeptide in the C-terminal region of CP. These results support the notion that the 
magnitude of the total antibody response cannot be used as a measure of protective immunity. 
Furthermore, protection versus disease lies in the immunodominance of specific epitopes. Epitope 
specificity should be taken into consideration when designing PCV2 vaccines. 
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a  b  s  t  r  a  c  t
Porcine  circovirus  associated  disease  (PCVAD)  encompasses  a group  of syndromes  linked  to  infection
with  porcine  circovirus  type  2 (PCV2).  Based  on  the  hypothesis  that  the immune  responses  to  vacci-
nation  versus  infection  are  quantitatively  and  qualitatively  different,  the  objective  of  this  study  was  to
evaluate  immunity,  virus  replication  and disease  protection  in pigs  vaccinated  with  PCV2  capsid  protein
(CP) and during  infection.  The  disease  model  included  dual  infection  with  PCV2  and porcine  reproductive
and  respiratory  syndrome  virus  (PRRSV),  a virus  known  to enhance  disease  progression  and  severity.  The
principal  effect  of  PRRSV  infection  was to increase  peak  PCV2  viremia  by  almost  40-fold;  however,  PCV2
failed  to show  a reciprocal  effect  on  PRRSV.  In vaccinated  pigs,  there  was no  evidence  of disease  or  PCV2
replication  following  dual  virus  challenge.  Immunity  following  vaccination  favored  PCV2  neutralizing
activity;  whereas,  PCV2  infection  and  disease  produced  high  levels  of  non-neutralizing  antibody,  primar-
ily  directed  against  a polypeptide  in  the  C-terminal  region  of  CP.  These  results  support  the  notion  that  the
magnitude  of  the total  antibody  response  cannot  be used  as  a measure  of  protective  immunity.  Further-
more,  protection  versus  disease  lies  in the  immunodominance  of speciﬁc  epitopes.  Epitope  speciﬁcity
should  be taken  into  consideration  when  designing  PCV2  vaccines.
© 2012 Elsevier Ltd. All rights reserved.
1. Introduction
First described in Canada in the early 1990s, porcine circovirus-
associated disease (PCVAD) has emerged as an economically
important disease worldwide [1,2]. A central feature of PCVAD is the
involvement of porcine circovirus type 2 (PCV2). PCVAD includes a
set of syndromes characterized by a variety of clinical disease signs,
which present alone or in combination, including wasting, diarrhea,
respiratory distress, dermatitis, and reproductive failure (reviewed
in [3–5]). The most common PCV2 syndrome is porcine multi-
systemic wasting syndrome (PMWS), which is characterized by
wasting, lymphadenopathy, immune suppression, and lymphoid
depletion. In 2008, we identiﬁed PCV2 as the source of reduced
growth in apparently asymptomatic herds [6].  Although PCVAD is
generally considered to be slow and progressive, a peracute syn-
drome, known as acute pulmonary edema (APE), has appeared in
∗ Corresponding author. Tel.: +1 785 532 4631; fax: +1 785 532 4481.
E-mail address: browland@vet.k-state.edu (R.R.R. Rowland).
some vaccinated herds [7].  The clinical manifestation and severity
of PCVAD are linked to a variety of co-factors, such as the dis-
ease potential of the PCV2 isolate [8,9], the presence of pathogenic
or opportunistic infections [10], host genetics [11–13],  and use of
immunostimulating agents, such as vaccines [14,15].
PCV2 is a small DNA virus possessing a 1.7 kb circular, single-
stranded genome surrounded by a homopolymer capsid [16]. PCV2
isolates are divided into two  main genotypes, known as PCV2a and
PCV2b [6,17,18]. A third genotype, designated PCV2c, includes a
small group of historical isolates identiﬁed in Denmark [19]. The
genotypic classiﬁcation of PCV2 is complicated by the appearance of
ﬁeld isolates possessing both PCV2a and PCV2b sequences [20,21].
The ambisense PCV2 genome is dominated by three open reading
frames (ORFs). The 233 amino acid capsid protein (CP) is coded for
by ORF2.
Recombinant vaccines containing only PCV2a CP are effective
in reducing morbidity and mortality and improve overall growth
performance, even in pigs without overt clinical signs [6,22–24].
Even though PCV2-infected pigs produce high levels of CP-speciﬁc
antibody, the onset and severity of PCVAD is correlated with
0264-410X/$ – see front matter ©  2012 Elsevier Ltd. All rights reserved.
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Table 1
Experimental groups and outcomes.
Group Description n Treatment Mortalityb
Vaccine a PCV2 PRRSV
1 CN Control 7 − − − 0
2  VX Vaccine only 7 + − − 0
3  PR PRRSV only 7 − − + 0
4 PC PCV2  only 7 − + − 0
5 VX-PC  Vaccine; PCV2 7 + + − 0
6  PC-PR PCV2+PRRSV 7 − + + 3 (15c, 24d,  28e)
7  VX-PC-PR Vaccine; PCV2+PRRSV 7 + + + 0
a Vaccinated with two doses of a recombinant baculovirus expressed PCV2 capsid protein product (Intervet/Schering-Plough Animal Health).
b Mortality = death or euthanasia of moribund pigs. The numbers in parenthesis indicate the day after virus challenge that deaths occurred.
c Lungs showed diffuse interstitial inﬂammation (clinical severity score of 4, on a scale of 1–4). Pathology was similar to PRRS with the likely contribution of a bacterial
infection. Lymph nodes were positive for PCV2 IHC staining.
d Lungs showed acute edema, hemorrhage and accumulation of macrophages in alveoli. Marked lymphocyte depletion in lymph nodes with scattered multinucleated giant
cells.  Lymph nodes were positive for PCV2 IHC staining.
e Euthanized. Lungs with neutrophilic bronchitis and atelectasis. Positive for PCV2 IHC staining in lymph nodes.
the absence or decreased levels of PCV2 neutralizing antibodies
[25–28]. Based on the hypothesis that the immune responses to
vaccination versus infection are quantitatively and qualitatively
different, the objective of this study was to evaluate immunity,
virus replication, and disease protection in pigs vaccinated with
PCV2 capsid protein (CP). Experimental challenge models, which
incorporate PCV2 alone, produce virus replication, but with only
mild or subclinical disease [29–32].  The unique aspect of this study
was the incorporation of a PCV2 disease model which included dual
infection with a “matched set” of PCV2b and PRRSV isolates, derived
from a pig with PMWS.
2. Materials and methods
2.1. Pigs and experimental challenge
All animal experiments were performed after approval by the
Kansas State University and Iowa State University institutional
animal use and biosafety committees. PCV2-negative pigs were
derived from conventional sows as described in Opriessnig et al.
[33]. Brieﬂy, prior to farrowing, sows were selected on the basis of
a PCV2 IFA titer less than 320. Approximately two  weeks after far-
rowing, piglets were screened and selected from four different sow
litters based on low antibody titers (less than 320 immunoﬂoures-
cent assay titer) to PCV2 and negative results by PCR for PCV2 DNA
in serum. Upon arrival at the challenge facility, the four week-old
pigs were conﬁrmed negative for PCV2 and PRRSV by PCR and then
assigned to one of seven treatment groups (see Table 1). Groups
were balanced according to sex, sow litter, and weight. At ﬁve
weeks of age (study day 0), groups 2, 5, and 7 were vaccinated
according to label instructions using a commercial baculovirus-
expressed PCV2 ORF2 product (Intervet/Schering-Plough Animal
Health). As per instructions, the second vaccine dose was adminis-
tered three weeks later. Groups 1, 3, 4, and 6 were left unvaccinated.
Two weeks after the second vaccine dose (study day 34), the pigs
were challenged with PCV2 alone (groups 4 and 5), PRRSV alone
(group 3), PCV2 plus PRRSV (groups 6 and 7) or mock-challenged
(groups 1 and 2).
After virus challenge, all pigs were monitored daily for clini-
cal signs and blood samples were collected weekly. Body weights
were measured at the time of challenge and at the termination of
the study. At 44 days after challenge (study day 78), all pigs were
humanely euthanized with an intravenous overdose of sodium pen-
tobarbital. At necropsy, lung, kidney and lymphoid tissues were
collected for PCV2 immunohistochemistry (IHC) and histopathol-
ogy.
2.2. Viruses and infection
The PCV2/PRRSV challenge inoculum originated from a pig that
succumbed to severe PMWS.  Titration of PCV2 was performed
on swine testicle (ST) cells [34]. Brieﬂy, serial 10-fold dilutions
of lymph node homogenate were plated in quadruplicate onto
rapidly dividing ST cells in a 96-well tissue culture plate (Fal-
con). Dilutions were made in EMEM (Sigma–Aldrich) containing
7% fetal bovine serum (Sigma–Aldrich; FBS) and 50 g/ml of gen-
tamicin (Lonza; EMEM-FBS-Gent). Following a 3 day incubation at
37 ◦C and 5% CO2, the cells were ﬁxed with acetone and stained
with ﬂuorescein isothiocyanate (FITC)-labeled porcine anti-PCV
(Veterinary Medical Research and Development, Inc.; VMRD). The
50% tissue culture infection dose (TCID50) per gram of lymph
node homogenate was calculated by the method of Spearman
and Karber [35]. The homogenate contained approximately 108
TCID50/g of PCV2. Sequence analysis showed the isolate to be of the
PCV2b genotype (Genbank accession #JQ692110). The homogenate
material was tested and conﬁrmed negative for common viruses
including inﬂuenza and parvovirus, but was positive for PRRSV.
PRRSV was  recovered from the homogenate by isolation on MARC-
145 cells, as previously described [36]. The homogenate was ﬁltered
through a 0.22 m ﬁlter (Fisherbrand) to remove bacteria. To pre-
pare a PRRSV challenge stock, the virus was passaged an additional
two times on MARC-145 cells and stored at −80 ◦C. The quantity of
PRRSV was  107 TCID50/ml, as determined by titration on MARC-145
cells. Brieﬂy, serial 1:10 dilutions of virus stock were prepared in
EMEM-FBS-Gent and added, in quadruplicate, to conﬂuent MARC-
145 cells in a 96 well plate. The cells were incubated for 3 days
at 37 ◦C and 5% CO2; then analyzed for virus induced cytopathic
effects. The TCID50/ml  of homogenate was calculated by the method
of Spearman and Karber [35].
For challenge with PCV2 alone, the ﬁltered homogenate was
heat-treated at 60 ◦C for 30 min  to inactivate PRRSV and other
heat-labile viruses. For dual challenge, PRRSV was  added back
to the heat-treated homogenate material. Pigs were challenged
intranasally with 105 TCID50 of PRRSV and/or 105 TCID50 PCV2 in
3 ml  of MEM.
2.3. Immunohistochemistry for PCV2 antigen
IHC staining for PCV2 antigen was performed on parafﬁn-
embedded tissue sections as routine diagnostic assays performed
by personnel within the Kansas State Veterinary Diagnostic Labo-
ratory (KSVDL). Upon collection, tissues were immediately placed
in 10% buffered formalin. After processing, parafﬁn-embedded
sections were mounted on slides, deparafﬁnized and stained
using an automated procedure (NexES IHC Staining Module,
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Ventana Medical). A rabbit anti-PCV2 polyclonal antibody was
used for the detection of PCV2 antigen. Bound rabbit antibody
was detected with biotinylated goat anti-rabbit (H + L) IgG (Ven-
tana Medical) followed by avidin-horseradish peroxidase and DAB
chromogen (Ventana Medical). Slides were counterstained with
hematoxylin.
2.4. Measurement of PCV2 and PRRSV antibody
Antibody assays for detection of total and neutralizing antibody
were performed as routine diagnostic assays within the KSVDL.
Total PCV2 antibody in serum was measured by indirect ﬂuorescent
antibody assay (IFA). Brieﬂy, rapidly dividing ST cells, maintained in
EMEM-FBS-Gent on 96 well plates, were infected with a laboratory
isolate of PCV2b. Three days later, the plates were ﬁxed for 10 min
in 80% acetone. Serum samples were added at an initial dilution of
1:40 followed by serial 1:2 dilutions. Samples were diluted in PBS
with 10% FBS (PBS-FBS) and incubated for two hours at room tem-
perature. After washing with PBS, FITC-labeled goat anti-pig (H + L)
antibody (Jackson Labs) diluted 1:2000 in PBS-FBS was  added to
each well. Plates were incubated for two hours at room tempera-
ture, washed, and viewed on an inverted ﬂuorescence microscope.
The antibody titer for each sample was calculated as the reciprocal
of the last serum dilution that exhibited ﬂuorescence staining and
reported as log2(40 × 1/dilution).
For the measurement of virus neutralizing activity (NA), four
replicate (100 l each) 1:2 serial dilutions of sera were mixed with
100 TCID50 of PCV2b and incubated for 1 h at 37 ◦C. Well contents
were transferred onto day-old ST cells in 96-well plates, incubated
for three days at 37 ◦C, ﬁxed and stained with undiluted FITC-
labeled anti-PCV2 (VMRD). A positive control from a vaccinated pig
and negative control from an antibody negative cesarean-derived
colostrum-deprived (CDCD) pig were included with each assay.
Wells were considered positive for PCV2-speciﬁc neutralization
if greater than 90% reduction in PCV2-speciﬁc ﬂuorescence was
detected. The results were reported as the log2 NA50 per ml  as
determined by the method of Spearman and Karber [35].
PRRSV antibody was measured using a commercially available
ELISA (PRRS X3, IDEXX). The results were reported as a sample to
positive (S/P) ratio. A S/P ratio greater than 0.39 was considered
positive for PRRSV antibody.
PCV2 capsid polypeptide ELISA was performed as previously
described [37]. Brieﬂy, CP polypeptides were cloned from a
PCV2b isolate (Genbank accession# HQ713495) and expressed in
Escherichia coli.  Ninety-six well ELISA plates (Costar) were coated
with 100 l of puriﬁed CP(43-135), CP(160-233), or CP(43-233) at
a concentration of 4 g/ml and incubated overnight at 4 ◦C. After
incubation, plates were washed with PBS containing 0.01% Tween-
20 (Sigma–Aldrich; PBST) and blocked for a minimum of 1 h with
PBS containing 10% goat serum (Invitrogen; PBS-GS). After block-
ing, duplicate serum samples diluted in PBS-GS were added to
wells and incubated for 2 h at room temperature. Plates were then
washed and 100 l of peroxidase-labeled goat anti-swine antibody
(Accurate Chemical & Scientiﬁc Corp.) diluted 1:2000 in PBS-GS
was added to each well. After incubation at room temperature
for one hour, the plate was washed and 100 l of the chroma-
genic substrate ABTS (KPL) added to each well. Peroxidase activity
was detected by measuring absorbance at 405 nm using a Maxline
microplate reader (Molecular Devices Corporation). To compare
results across experiments, each ELISA plate included an inter-
nal positive control consisting of a high IFA antibody titer serum
reacted with the CP(43-233) polypeptide. Results are reported as
an antibody binding ratio, which was calculated as the A405 value
of the unknown sample minus background divided by the A405
value of the internal positive control minus background.
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Fig. 1. PCV2 and PRRSV viremia. PCR for PCV2 (A) and PRRSV (B) was performed
as  described in Materials and methods. Key: Group 1 – CN (closed squares), Group
2  – VX (open circles), Group 3 – PR (closed circles), Group 4 – PC (open squares),
Group 5 – VX-PC (closed diamonds), Group 6 – PC-PR (open triangles), Group 7 –
VX-PC-PR (closed triangles). Groups with the same letters at speciﬁc time points
indicate means that are not signiﬁcantly different (P > 0.05).
2.5. PCR for PCV2 and PRRSV nucleic acid
Viremia was measured using semi-quantitative TaqMan PCR
assays for PRRSV RNA and PCV2 DNA. PCR assays were performed
as routine diagnostic tests by personnel in the KSVDL. For PRRSV,
total RNA was isolated from serum using a MagMAXTM-96 Viral
RNA Isolation Kit (Applied Biosystems) according to the manufac-
turer’s instructions. Master mixes were prepared using the AgPath
IDTM NA & EU PRRSV kit (Applied Biosystems) and assays setup
as a one-step reverse transcriptase (RT) PCR reaction, according
to the kit instructions. The RT-PCR reactions were carried out on
a QST 7500 Real-Time PCR System (Applied Biosystems) in a 96-
well format. For the construction of a standard curve, dilutions of
template RNA, supplied by the manufacturer, were prepared and
assayed concurrently with the samples. PCV2 DNA was  assayed by
PCR using the same nucleic acid isolation method and was per-
formed using PCV2 speciﬁc primers and probes. The assay results
are reported as the Log10 of PCV2 DNA or PRRSV RNA copy number
per reaction.
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Fig. 2. PCV2 antigen in lymph nodes. IHC staining in parafﬁn-embedded sections shows the presence of PCV2 antigen by the red staining. (A) shows a representative result
for  tissues from pigs in group 1 (CN). (B) shows evidence of positive, but weak staining in a single pig in group 4 (PC). (C) is a photomicrograph representative of the three
pigs  in Group 6 (PC-PR) that died prior to end of the study. Panel D shows a photomicrograph that is representative for all pigs in group 7 (VX-PC-PR). Except for (C), the
results  are from lymph nodes collected 44 days after virus challenge.
2.6. Statistical methods
Statistical analysis was performed using GraphPad Prism ver-
sion 5.04 for Windows (GraphPad Software, San Diego, California).
IFA titers were 40 × log2 transformed prior to analysis. Repeated
measures data were analyzed by one way analysis of variance fol-
lowed by the Tukey post-test. Differences at speciﬁc time points
were analyzed by the Kruskal–Wallis test. If signiﬁcant differences
were detected, speciﬁc groups at time points were assessed using
Wilcoxon’s test. Non-repeated measures, such as antibody reac-
tivity to CP polypeptides, were assessed using the Kruskal–Wallis
test. If differences were detected, measures were further assessed
by Wilcoxon’s test. Signiﬁcant differences were accepted if P < 0.05.
3. Results
3.1. Clinical signs and pathology
Clinical signs and pathology were primarily restricted to the
dual-challenge (group 6) and PRRS only (group 3) groups. Both
groups showed signs of acute PRRS, including mild respiratory
distress. The clinical signs were more pronounced following dual
challenge, which resulted in the death of three pigs (see Table 1).
Histopathology indicated that death was the result of pneumonia
with the inﬁltration of neutrophils, an indicator of bacterial infec-
tion. One of the dead pigs showed marked lymphocyte depletion
in lymph nodes, an indication of PCVAD. The remaining groups
showed no clinical signs and appeared normal throughout the study
period. Histopathology, performed at the end of the study did not
identify lymphocyte depletion in pigs from the other groups.
The impact of infection on growth was determined by mea-
suring the average daily weight gain (ADWG). All groups were
balanced according to weight and sex and pigs were weighed
at the beginning and end of the study. Mean ADWG for the
group 1 (CN) and group 4 (PC) pigs was 0.76 ± 0.10 kg/day and
0.69 ± 0.07 kg/day, respectively. The mean for group 6 (PC-PR) pigs
was 0.61 ± 0.09 kg/day; however, only 4 of the 7 pigs survived to
the end of the study. For pigs vaccinated prior to dual challenge
(VX-PC-PR), ADWG was  0.71 ± 0.14 kg/day.
3.2. PCV2 and PRRSV viremia
All pigs were negative for PCV2 and PRRSV nucleic acid at the
beginning of the study and at the time of challenge. The results
for PCV2 viremia are summarized in Fig. 1A. By 15 days after
infection, all pigs in groups 4 (PC) and 6 (PC-PR) were positive for
PCV2 nucleic acid in serum. The principal difference between group
4 and group 6 was observed 23 days after challenge (study day 57),
when mean viremia for group 4 was  3.1 ± 0.4 log10 templates/rxn
versus 4.7 ± 1.1 log10 templates/rxn for group 6 (Fig. 1A). The dif-
ference in viremia was  signiﬁcant (P = 0.0042). By the end of the
study, PCV2 nucleic acid was still detected in all pigs in groups 4
and 6. For all other groups, PCV2 DNA was below detectable levels,
including pigs that were vaccinated prior to challenge, i.e. group 5
(PC-VS) and group 7 (PC-PR-VS).
Increased viremia in group 6 (PC-PR) pigs was  supported by the
presence of IHC staining for PCV2 antigen in lymphoid tissues in
those pigs that succumbed to infection (see Fig. 2C). All other pigs
were negative for PCV2 antigen staining except for a single pig in
group 4 (PC) that showed areas of weak staining in a single lymph
node (see Fig. 2B). Representative results for control and vaccinated
pigs are presented in Fig. 2, panels A and D.
The results for PRRSV viremia are shown in Fig. 1B. Mean PRRSV
viremia peaked at approximately 8 days after challenge for groups
3, 6 and 7. By 44 days, PRRSV nucleic acid was below detectable
levels in all groups. There was no statistical difference between
the PRRSV-infected groups at any day after infection. Pigs not
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Fig. 3. PCV2 immunoﬂuorescent antibody assay (IFA) and virus neutralizing activity
(NA) responses. IFA (A) and NA (B) were measured in serum samples as described
in  Materials and Methods. IFA results are reported as log2(40 × 1/dilution) and NA
as  the log2 NA50 per ml.  Key: group 1 – CN (closed squares), group 2 – VX (open
circles), group 3 – PR (closed circles), group 4 – PC (open squares), group 5 – VX-PC
(closed diamonds), group 6 – PC-PR (open triangles), group 7 – VX-PC-PR (closed
triangles). Groups with the same letter at a speciﬁc time point indicate means that
are  not signiﬁcantly different (P > 0.05).
challenged with PRRSV remained negative for PRRSV throughout
the study.
3.3. PCV2 antibody response
Mean PCV2 IFA endpoints for all treatment groups are shown in
Fig. 3A. At the time of entry into the challenge facility, most pigs
possessed detectable levels of PCV2 antibody, the likely result of
maternally-derived antibody (MDA) acquired during suckling. By
the time of virus challenge, PCV2 antibody IFA titers were below
detectable levels in the non-vaccinated groups. Pigs in group 1
(CN) and group 3 (PR) remained PCV2 IFA negative throughout the
remainder of the study. For the vaccinated groups, PCV2 antibody
was present by 21 days after the ﬁrst vaccine dose and peaked by
day 34. At 21 days after PCV2 challenge (study day 42), the IFA titers
in group 4 (PC) and group 6 (PC-PR) reached detectable levels. Peak
antibody levels for infected pigs were the same as the vaccinated
groups.
In contrast to total antibody, there were distinct differences in
PCV2 neutralizing activity between the vaccinated pigs (groups 2,
5, and 7) and unvaccinated PCV2-infected pigs (groups 4 and 6;
see Fig. 3B). The NA for all vaccinated groups was  approximately
16 (log2 = 4) compared to 4 (log2 = 2) for the unvaccinated PCV2-
infected groups. Together, the results show that vaccination and
infection result in similar levels of total antibody, but neutralizing
activity during natural infection is signiﬁcantly impaired.
PRRSV antibody ELISA, performed at the end of the study, con-
ﬁrmed that all pigs challenged with PRRSV (groups 3, 6 and 7)
were seropositive for PRRSV, while pigs in the remaining groups
remained seronegative (data not shown).
3.4. Recognition of PCV2 CP polypeptides
Previously, we demonstrated that vaccination resulted in anti-
body reactivity towards CP(43-43-233). In contrast, PCVAD pigs
recognized small CP polypeptide fragments, primarily located in
the C-terminal region. Finer mapping with synthesized 20mer
oligopeptides identiﬁed a small epitope, CP(169-180) recognized
by PCVAD pigs but not vaccinated pigs [37]. Therefore, the pattern of
reactivity against the three polypeptides was used to characterize
the nature of the antibody response; i.e. consistent with vaccination
versus disease. For the purpose of this study, ELISA was per-
formed using an N-terminal polypeptide, CP(43-135), C-terminal
fragment, CP(160-233), and CP(43-233). As shown in Fig. 4A, the
mean response for group 1 (CN) pigs showed only background lev-
els of binding to all polypeptides fragments. The vaccine only group,
group 2, showed high binding activity against CP(43-233) and
background binding for CP(43-135) and CP(160-233). As shown in
Fig. 4B, infection with PCV2 alone showed reactivity against CP(43-
233) and CP(160-233) with minimal reactivity towards CP(43-135).
Vaccination prior to PCV2 challenge resulted in response similar to
vaccine. The response of dual infected pigs is shown in Fig. 4C. Anti-
body reactivity was  elevated against CP(160-233) and CP(43-233),
but the results were not signiﬁcantly different between the three
polypeptides. However, vaccination prior to challenge showed a
response similar to the vaccine only group.
4. Discussion
In this study, the PCV2 vaccine response was  evaluated in the
context of a PCVAD challenge model. Dual challenge with PCV2
and PRRSV resulted in high mortality and the presence of clin-
ical signs and pathology associated with PCVAD. One effect of
PRRSV was  increased PCV2 infection as determined by the pres-
ence of increased PCV2 nucleic acid in the blood and deposition
of PCV2 antigen in lymph nodes (Figs. 1 and 2), supporting pre-
vious observations following PCV2-PRRSV infection [38–41].  The
mechanistic role of co-factors, such as PRRSV, in the onset of
PCVAD has remained largely unclear. One possibility relates to
PRRSV modulation of host immunity, by increasing the number of
PCV2-permissive lymphocytes through PRRSV-induced blastogen-
esis, or by suppressing anti-PCV2 immune responses (reviewed by
Opriessnig and Halbur [38]).
Experimental and ﬁeld studies have clearly demonstrated the
efﬁcacy of PCV2 vaccines in reducing viremia, eliminating PCVAD,
and increasing growth performance [6,22–24]. The data from this
study provide further insights regarding the nature of the antibody
response during infection and after vaccination. The IFA results
showed that PCV2 infection and vaccination result in similar levels
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Fig. 4. Antibody response of pigs to PCV2 capsid polypeptides. Serum samples from
non-vaccinated and vaccinated pigs were reacted with polypeptides that covered
amino acids 43-135, 160-233 and 43-233 of CP. Results for non-infected groups are
in  panel A, groups infected with PCV2 only in (B), and groups infected with PCV2
and  PRRSV in (C). The dotted line separates vaccinated groups (right side) from non-
vaccinated groups (left side). The assay was performed with sera collected at 44 days
after virus challenge. Mean antibody ratios with the same letter are not signiﬁcantly
different (P > 0.05). *Due to mortality, only 4 pigs were included in the analysis for
group 6. All other groups included 7 pigs.
of total serum antibody (Fig. 3A). However, vaccination generated
approximately four times the amount of virus neutralizing activity
compared to infection with PCV2 alone or with PCV2 and PRRSV
(Fig. 3B). Therefore, increased NA in vaccininated pigs represents
a quantitative difference between vaccine and natural infection.
This study also provides evidence for a qualitative difference in the
antibody response following infection versus vaccination. Previ-
ously, we identiﬁed an immunodominant epitope in the C-terminal
region of CP that is recognized by sera from PCVAD affected pigs.
The results from this study showed that all vaccinated groups
recognized only the large CP(43-233) polypeptide and possessed
relatively high NA (see Fig. 3, panel B and Fig. 4, right side of dashed
line). In contrast, PCV2 pigs infected showed reactivity to both
CP(43-233) and CP(160-233) and exhibit relatively low NA (see
Fig. 3, panel B and Fig. 4, left side of dashed line). We  propose a
model in which immune modulation during active PCV2 infection
leads to the production of antibodies primarily directed towards
CP(169-180), located in the CP(160-233) fragment. Antibodies
speciﬁc to this region are non-neutralizing. Response to the
CP(169-180) epitope is likely generated by the immune response
to free CP monomer and/or smaller CP fragments produced by
PCV2-infected cells. In contrast, the PCV2 virus like particle (VLP)
does not display this epitope. The locations of CP(169-180) within
the X-ray crystal structure of the PCV2 CP monomer and VLP [42]
provide further support for this model. In the monomer form of CP,
CP(169-180) is exposed on an outer loop where it induces a speciﬁc
antibody response, whereas, in the context of the VLP, CP(169-180)
is buried within the CP structure and therefore, hidden [43]. We
propose that protective antibodies induced by vaccination are
generated in response to the VLP. Baculovirus-expressed CP,
which is incorporated into two  of the ﬁve currently available
commercial PCV2 vaccines, likely expresses CP in the form of a VLP
[42]. Therefore, the form of the CP antigen should be taken into
consideration when developing PCV2 vaccines.
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